Actively Recruiting
Phase II Study of TAR-0520 Gel to Prevent Folliculitis Caused by EGFR Inhibitors in Metastatic Colorectal Cancer Patients
Led by Tarian Pharma · Updated on 2025-02-10
60
Participants Needed
3
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the use of TAR-0520 gel to prevent and treat folliculitis caused by EGFR inhibitor drugs in patients with metastatic colorectal cancer. These skin side effects commonly appear within 1 to 2 weeks of treatment with cetuximab or panitumumab and affect areas like the face, upper torso, and scalp. This Phase II trial aims to confirm the safety of TAR-0520 gel and explore its effect on reducing the extent and severity of this folliculitis. Participants will be randomly assigned to receive either the active TAR-0520 gel containing brimonidine tartrate or a placebo gel without it. They will apply the gel once daily for 7 days during each chemotherapy cycle, followed by a treatment-free period until the next cycle starts. The study covers 4 chemotherapy cycles, lasting at least 56 days. During the trial, researchers will monitor safety by measuring treatment-emergent adverse events at baseline and on days 14, 28, 42, and 56. They will also assess how well TAR-0520 gel prevents folliculitis at these same time points. Participants will be expected to apply the gel themselves or have a caregiver assist, and they will be evaluated regularly throughout the study period.
CONDITIONS
Brief Title
TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis
Research Team
J
Janusz Czernielewski, MD
A
Alexandra Lamquin, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here